{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:27:49Z","timestamp":1790389669415,"version":"4.1.0"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,13]]},"DOI":"10.18632\/oncotarget.4772","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"32228-32243","source":"Crossref","is-referenced-by-count":74,"title":["A phase 1\/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer"],"prefix":"10.18632","volume":"6","author":[{"given":"Eveline M.","family":"Dijkgraaf","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia J.A.M.","family":"Santegoets","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An K.L.","family":"Reyners","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Goedemans","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"Nijman","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte I.E.","family":"van Poelgeest","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arien R.","family":"van Erkel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.H.B.M.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toos A.H.H.","family":"Daemen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus J.M.","family":"van der Hoeven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.M.","family":"Melief","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marij J.P.","family":"Welters","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Kaye","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Kaye","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Dranoff","year":"2011","journal-title":"Nature"},{"key":"4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Bhatia","year":"2012","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"OF8","DOI":"10.1158\/2159-8290.CD-ND2013-013","article-title":"Trials show delayed recurrence in ovarian cancer","volume":"3","author":"Bender","year":"2013","journal-title":"Cancer Discov"},{"key":"6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Coukos","year":"2003","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Ritter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes","volume":"108","author":"van","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Fujii","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Kalinski","year":"2011","journal-title":"Cancer Res"},{"key":"11","article-title":"Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer","volume":"10","author":"van der Burg","year":"2014","journal-title":"Oncoimmunology"},{"key":"12","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","article-title":"Relationship between B7-H4, regulatory T-cells, and patient outcome in human ovarian carcinoma","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/imt.11.20","article-title":"Immunity and immune suppression in human ovarian cancer","volume":"3","author":"Knutson","year":"2011","journal-title":"Immunotherapy"},{"key":"14","first-page":"v188","article-title":"Role of gemcitabine in ovarian cancer treatment","volume":"5","author":"Scambia","year":"2006","journal-title":"Ann Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Ostrand-Rosenberg","year":"2010","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Albelda","year":"2005","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.27990","article-title":"Low-dose gemcitabine depletes regulatory T-cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Bazhin","year":"2013","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells","volume":"129","author":"Pascolo","year":"2011","journal-title":"Int J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-14-2142","article-title":"Vaccine-induced tumor necrosis factor-producing T-cells synergize with Cisplatin to promote tumor cell death","volume":"21","author":"Melief","year":"2015","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","article-title":"Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer","volume":"15","author":"van der Burg","year":"2009","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ijc.22710","article-title":"P53-specific T-cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy","volume":"121","author":"Offringa","year":"2007","journal-title":"Int J Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/ijc.24597","article-title":"Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial","volume":"125","author":"Valentijn","year":"2009","journal-title":"Int J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"E670","DOI":"10.1002\/ijc.27388","article-title":"Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study","volume":"131","author":"Melief","year":"2012","journal-title":"Int J Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/ijc.27819","article-title":"Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I\/II clinical trial","volume":"132","author":"Drijfhout","year":"2013","journal-title":"Int J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.189.3.521","article-title":"Type I interferons keep activated T-cells alive","volume":"189","author":"Mitchell","year":"1999","journal-title":"J Exp Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Schreiber","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1359-6101(01)00035-1","article-title":"Endogenous type I interferons as a defense against tumors","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"28","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood-2005-03-1154","article-title":"Natural-killer cells and dendritic cells: \u201cl'union fait la force\u201d","volume":"106","author":"Vivier","year":"2005","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.4049\/jimmunol.172.9.5363","article-title":"Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T-cell responses against human tumor antigens","volume":"172","author":"Rivoltini","year":"2004","journal-title":"J Immunol"},{"key":"30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.imbio.2010.10.003","article-title":"IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity","volume":"216","author":"Ferrantini","year":"2011","journal-title":"Immunobiology"},{"key":"31","first-page":"6187","article-title":"Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells","volume":"62","author":"Melief","year":"2002","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/0008-5472.CAN-07-3166","article-title":"Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen","volume":"68","author":"Offringa","year":"2008","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","article-title":"\u201cMIATA\u201d-minimal information about T-cell assays","volume":"31","author":"Davis","year":"2009","journal-title":"Immunity"},{"key":"36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells4010001","article-title":"Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis","volume":"4","author":"Judkowski","year":"2014","journal-title":"Cells"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Dijkgraaf, Santegoets, Reyners, Goedemans, Wouters, Kenter, van Erkel, van Poelgeest, Nijman, van der Hoeven, Welters, van der Burg, kroep. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u00e1 2b in patients with recurrent epithelial ovarian cancer. 2014. Submitted.","DOI":"10.1093\/annonc\/mdv309"},{"key":"38","first-page":"1858","article-title":"Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice","volume":"9","author":"Fidler","year":"2003","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/1079990041689647","article-title":"Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice","volume":"24","author":"Schmidt-Wolf","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00001813-200210000-00001","article-title":"Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer","volume":"13","author":"Unger","year":"2002","journal-title":"Anticancer Drugs"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T16:15:43Z","timestamp":1589386543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":40,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,10,13]]}},"alternative-id":["4772","26334096"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4772","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,14]]}}}